GlaxoSmithKline Pharmaceuticals Ltd. - Research Center

---

Results

• Quarterly
• Half yearly
• Annual

Statement

• Balance sheet
• P&L
• Cash flow

More

• Dividend
• Bonus
• Share holding
• Capital structures
• Ratio

Sep ' 23	Sep ' 22	Mar ' 22	Sep ' 21	Sep ' 20

Sales

1,691.40

1,635.07

1,599.90

1,764.99

1,528.04

Operating profit

427.83

404.85

370.08

425.08

319.37

Interest

0.71

1.07

0.85

1.14

1.96

Gross profit

492.39

453.73

398.67

470.72

384.12

EPS (Rs)

20.43

18.43

80.72

19.07

11.07

Other income

65.27

49.95

29.44

46.78

66.71

Stock adjustment

-34.67

-116.86

7.88

4.25

-22.82

Raw material

225.18

255.53

240.13

312.25

252.33

Power and fuel

-

-

-

-

-

Employee expenses

310.21

293.16

282.43

327.80

305.93

Excise

-

-

-

-

-

Admin and selling expenses

-

-

-

-

-

Research and development expenses

-

-

-

-

-

Expenses capitalised

-

-

-

-

-

Other expenses

762.85

798.39

699.38

695.61

673.23

Provisions made

-

-

-

-

-

Depreciation

34.47

32.18

33.22

35.31

43.73

Taxation

129.10

112.36

295.34

112.36

88.80

Net profit / loss

346.12

312.24

1,367.47

323.05

187.46

Extra ordinary item

17.30

3.05

1,297.36

-

-64.13

Prior year adjustments

-

-

-

-

-

Equity capital

169.41

169.41

169.41

169.41

169.41

Equity dividend rate

-

-

-

-

-

Agg.of non-prom. shares (Lacs)

-

-

-

-

-

Agg.of non promotoholding (%)

-

-

-

-

-

OPM (%)

25.29

24.76

23.13

24.08

20.90

GPM (%)

28.03

26.93

24.47

25.98

24.09

NPM (%)

19.70

18.53

83.93

17.83

11.75